Weight loss injection eligibility depends on the medicine, clinical assessment and the route through which treatment is offered. NHS access criteria can differ from a medicine’s licensed indication or a private provider’s assessment. A refusal should lead to an explanation and discussion of suitable support, not a judgement about someone’s effort.

Weight loss injection eligibility: BMI and health assessment

Eligibility for weight loss injections often depends on clinical guidelines, which consider factors such as body mass index (BMI), underlying health conditions, and the presence of obesity-related complications. For example, individuals who are close to what is medically defined as a healthy weight may not qualify for these treatments. This is because many weight loss medications are approved primarily for people with obesity or significant overweight-related health risks.

Healthcare providers and clinics may also assess other factors such as eating behaviours, psychological health, and lifestyle circumstances. These considerations should be discussed individually. Stress, emotional eating or family commitments do not by themselves establish a universal exclusion rule.

Lived Experience and Challenges

Many people report struggling with urges to overeat that feel overwhelming, sometimes described as physical pain. Managing such urges alongside demanding jobs and family responsibilities can be exhausting. These lived experiences highlight that weight management is multifaceted, involving not just physical but emotional and social dimensions.

Rejection from weight loss injection programmes can be frustrating, especially when individuals feel close to their target weight or have tried multiple approaches. It is important to recognise that such decisions are often made with safety and long-term health in mind, rather than as a personal judgement.

NHS eligibility, private assessment and other support

Tirzepatide and semaglutide are established prescription options for eligible patients; they should not be described collectively as mostly early-stage research. Ask which medicine and indication the assessment considered, which access criteria apply, and what review or alternative support is available.

A research-use product listing is not an alternative route to a prescription medicine. Personal decisions require a qualified prescriber.

Related reading

Explore BMI and off-label prescribing questions, discussing treatment and privacy.

Sources

NHS: tirzepatide — https://www.nhs.uk/medicines/tirzepatide/

NHS: overweight and obesity — https://www.nhs.uk/conditions/overweight-and-obesity/